MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Triple Helix _ Translation, Commercialization, Technology Transfer, SBIR/STTR, OTA, NonTraditional / New Business Models
Triple Helix: Regional Innovation Clusters (RIC)s
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
*Industry: Ireland
AbbVie Inc. (NYSE:ABBV)
Organization & Developments: AbbVie
Parents
AbbVie Inc. (NYSE:ABBV)
Children
*Humira (adalimumab)
*Organization & Developments: AbbVie (Archives 2017-2018)
*Organization & Developments: AbbVie (Archives 2019-2021)
*Specialty-focused, research-based biopharmaceutical company
*The research-based pharmaceuticals company is named AbbVie.
2022: AbbVie - 5 Aspects Of Q3 Earnings Persuading Me To "Buy The Dip"_seekingalpha.com
2022: AbbVie: Clouds Keep Thickening Due To Lack Of Revolutionary Drugs_ seekingalpha.com
2022: AbbVie: Get Ready For Humira 2.0_ seekingalpha.com
2022: AbbVie: Paid To Wait_ seekingalpha.com
2022: AbbVie: Small Hurdle_seekingalpha.com
2022: AbbVie: Valuation Attractive Due To Humira Headwinds_seekingalpha.com
2022: Outlook For AbbVie Continues To Look Favorable_seekingalpha.com
2023: 'Hold' In The Short Term, 'Buy' On Humira-Inspired Dips (NYSE:ABBV)
2023: 2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To Benefit_ seekingalpha.com
2023: 4.5%-Yielding AbbVie Is One Of My Favorite Value Plays For 2024_ seekingalpha.com
2023: Abbott And AbbVie: 10 Years Of Blue Chip Outperformance, More To Come_ seekingalpha.com
2023: AbbVie Q3 Earnings Preview: Tough Comparison For Humira Shouldn't Derail Growth Plans
2023: AbbVie Stock Still A Hold Despite Positive Third Quarter 2023 Results (NYSE:ABBV)
2023: AbbVie: Get Ready For More Painful Downside_seekingalpha.com
2023: AbbVie: Why The Company Is Still Overvalued_ seekingalpha.com
2023: AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why
2023: AbbVie’s Rinvoq Lands FDA Approval as First Oral Drug for Crohn’s Diseas_ medcitynews
2023: Betting on cell memory, AbbVie pays Immunome $30M upfront to further antibody research
2023: Unveiling AbbVie's Hidden Risks: Cautionary Notes For Investors
2023: What To Expect After The Failed AbbVie Drug Sales_ seekingalpha.com
2024: AbbVie (ABBV): Growth Driven by Skyrizi, Rinvoq, and Strategic Acquisitions
2024: AbbVie Beats Q3 Estimates as Skyrizi, Rinvoq Pick Up Slack for Humira
2024: AbbVie Inc. (ABBV) Projects Mid-Single-Digit Sales Growth Over Next 3 Years
2024: AbbVie Q2 Preview: Upgrade To Buy - Better Late Than Never
2024: AbbVie Q4 Earnings Preview: Few Clouds On Horizon Thanks To Masterful Management (Rating Upgrade)
2024: AbbVie Stock: I Was So Wrong, But This Is Way Too Fast
2024: AbbVie: $200 Peak (Rating Downgrade)
2024: AbbVie: Bulletproof Fundamentals
2024: AbbVie: Comeback Expected After Humira Patent Expiration
2024: AbbVie: Emraclidine's Failure Eliminates An Important Growth Driver_ seekingalpha.com
2024: AbbVie: Game Changer
2024: AbbVie: Great To Be Proven Wrong - Still Not A Buy_seekingalpha.com
2024: AbbVie: Pullback Is A Golden Opportunity For Dividend And Growth Investors
2024: AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision
2024: AbbVie: Time To Lock In Gains (Rating Downgrade)_ seekingalpha.com
2024: AbbVie: Turnaround Lurking After The Correction Pain (Upgrade
2024: AbbVie: Upgrading To 'Strong Buy' After Pullback_seekingalpha.com
2024: Abbvie: Why The 3.7% Yielder With 10% Annual Return Potential Remains One Of My Go-To Investments For Income And Growth
2024: AbbVie's $9B schizophrenia prospect flunks phase 2 trials, handing advantage to BMS
2024: AbbVie’s $8.7B Cerevel Buy Starts to Pay off With Phase III Parkinson’s Win
2024: Betting Big On AbbVie: A Prescription For Growth And Dividends_ seekingalpha.com
2024: Despite Neuroscience Setback, AbbVie Has Strong Recovery Ahead
2024: Is AbbVie Still A Strong Buy After Fantastic Gains? (Rating Downgrade)
2024: Three ways AI is changing drug discovery at AbbVie
2024: Unveiling AbbVie's Winning Strategy In Pharmaceutical Innovation (Rating Upgrade)
2024: What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine
2024: Why AbbVie Remains One Of My Favorite Dividend Growers_ seekingalpha.com
2025: #7. Skyrizi (risankizumab-rzaa) AbbVie 2024 Sales: $11.718 billion 2023 Sales: $7.763 billion % Change: +50.9%
2025: AbbVie advances solid tumor agenda with FDA nod for lung cancer ADC Emrelis
2025: AbbVie Embraces Psychedelic Drug with Up-to-$1.2B Deal for Gilgamesh’s MDD Candidate
2025: AbbVie finally enters obesity race with $350M upfront for Gubra’s amylin
2025: AbbVie Has Immense Cash Flow Potential
2025: AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk_ seekingalpha.com
2025: AbbVie Q4 Earnings: Good 2025 Outlook Despite Enhanced Old And New Headwinds
2025: AbbVie Q4 Earnings: Strong Revenue Results, Ambitious Forecasts - A Buy With Caveats_ seekingalpha.com
2025: AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin
2025: AbbVie Steps Into The Ring In The Obesity Drug Wars
2025: AbbVie Steps Into The Ring In The Obesity Drug Wars_ seekingalpha.com
2025: AbbVie: A Biotech Powerhouse Generating Explosive EPS And Dividend Growth
2025: AbbVie: An Undervalued Dividend Aristocrat
2025: AbbVie's Gilgamesh deal highlights pharma's one-asset mind
AbbVie Ventures
Jumps
*Key People: AbbVie
Finance & Acquisition: AbbVie
Organization & Developments: AbbVie (Archives 2011-2016)